Design and interim safety analysis of GeparX trial

Bookmark and Share
Published: 4 Jun 2018
Views: 1046
Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany

Dr Loibl speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the trail arms and early indications from the Gepar X trial investigating denosumab as a neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules.

Dr Loibl also spoke with ecancer about the Gepar Nuevo trial, here

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.